13D Filing: Phase4 Partners Ltd and Albireo Pharma Inc. (ALBO)

Number of shares as to which such person has:

(i)	Sole power to vote or to direct the vote:

Phase4 Partners		1,065,447 shares
Phase4 III		1,065,447 shares
Phase4 GPLP		1,065,447 shares
Phase4 GP		1,065,447 shares
Dr. Alastair McKinnon		0 shares
Denise Scots-Knight, Ph.D.		0 shares
Charles Sermon		0 shares

(ii)	Shared power to vote or to direct the vote:

Phase4 Partners		0 shares
Phase4 III		0 shares
Phase4 GPLP		0 shares
Phase4 GP		0 shares
Dr. Alastair McKinnon		1,065,447 shares
Denise Scots-Knight, Ph.D.		1,065,447 shares
Charles Sermon		1,065,447 shares

(iii)

Sole power to dispose or to direct the disposition of:

Phase4 Partners		1,065,447 shares
Phase4 III		1,065,447 shares
Phase4 GPLP		1,065,447 shares
Phase4 GP		1,065,447 shares
Dr. Alastair McKinnon		0 shares
Denise Scots-Knight, Ph.D.		0 shares
Charles Sermon		0 shares

(iv)	Shared power to dispose or to direct the disposition of:

Phase4 Partners		0 shares
Phase4 III		0 shares
Phase4 GPLP		0 shares
Phase4 GP		0 shares
Dr. Alastair McKinnon		1,065,447 shares
Denise Scots-Knight, Ph.D.		1,065,447 shares
Charles Sermon		1,065,447 shares

(c) On January 30, 2018, 100,000 shares of Common Stock held by Phase4 GPLP, in its capacity as general partner of Phase4 III, were sold in open market transactions as follows:

Number of Shares of Common Stock			Price per Share*				Price Range
98,500			$	34.4006			$	34.40			$	34.71
1,500			$	37.0587			$	36.60			$	37.43

*The number of securities reported represent an aggregate number of shares executed by a broker-dealer in multiple market transactions over a range of prices. The price per share reported represents the weighted-average price (without regard to brokerage commissions and fees). The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission, upon request, the number of shares executed at each separate price within the range.

Except as set forth above, the Reporting Persons have not effected any transactions with respect to the shares of the Common Stock during the past 60 days.

(d) Not applicable.

(e) Not applicable.